Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Welcome back from the holiday weekend. Today we have some candor in ALL CAPS from Trump on Covid vaccines, glowy data from Ionis that could lead to an expanded approval for olezarsen, and more.
The need-to-know this morning
- United Therapeutics reported positive results from a Phase 3 study of its inhaled medicine Tyvaso in patients with idiopathic pulmonary fibrosis.
- Replimune Group said a meeting with FDA officials has been scheduled to discuss the recent rejection of its treatment for advanced melanoma.
Veteran drugmakers launch Corsera to fight heart disease
Biotech veterans John Maraganore, previously the CEO of Alnylam, and Clive Meanwell, previously the CEO of The Medicines Company, have teamed up before to develop drugs. Now they’re doing so again to launch Corsera Health, a startup aiming to prevent cardiovascular disease, STAT’s Allison DeAngelis writes. The company is developing an AI risk-prediction tool and a dual-target RNAi therapy against PCSK9 and angiotensinogen
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.